http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2536256-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da54f7ebbd2d9d8a82f92aca4d1b4e48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c36819c054f29562209fd22c3d23ff0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1045 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 |
| filingDate | 2004-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8831928b2e1242eda6eeb53910a8e68b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bdd4127fcf86cfbe1d9561b6f423da4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_262f49b70400052b4a1f5da468f7dd4c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16dbaf5bfeea38778cc3b1d59e26240e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9673d2af8705f5ee6f00fa3023431b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed614b9b162f6dc1ea676fc5ac1b46d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_360b4f98c3511d1ce5eaa6716d75a33b |
| publicationDate | 2013-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2536256-C |
| titleOfInvention | Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b |
| abstract | A specific binding member that binds human ED-B, wherein the specific binding member is labelled with an isotope selected from the group consisting of 76Br, 77Br, 123I, 124I, 131I and 211At and comprises an antigen-binding site that comprises an antibody VH domain and an antibody VL domain, wherein the antibody VH domain is selected from the group consisting of the L19 VH domain, and a VH domain comprising a VH CDR1, a VH CDR2 and a VH CDR3, wherein the VH CDR3 is the L19 VH CDR3 of SEQ ID NO. 3, the VH CDR1 is optionally L19 VH CDR1 of SEQ ID NO. 1, and the VH CDR2 is optionally L19 VH CDR2 of SEQ ID NO. 2; and wherein the antibody VL domain is optionally selected from the group consisting of the L19 VL domain, and a VL domain comprising a VL CDR1, a VL CDR2 and a VL CDR3, wherein the VL CDR3 is the L19 VL CDR3 of SEQ ID NO. 6, the VL CDR1 is optionally L19 VL CDR1 of SEQ ID NO. 4, and the VL CDR2 is optionally L19 VL CDR2 of SEQ ID NO. 5; the L19 VH domain and L19 VL domain sequences being disclosed in Pini et al. (1998) J. Biol. Chem. 273: 21769-21776; wherein the specific binding member comprises a mini-immunoglobulin comprising said antibody VH domain and antibody VL domain fused to eS2-CH4 and dimerized or comprises a whole IgG1 antibody molecule; also methods and uses employing such a specific binding member. |
| priorityDate | 2003-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 355.